Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

First Posted Date
2017-11-17
Last Posted Date
2020-05-28
Lead Sponsor
St. Petersburg State Pavlov Medical University
Target Recruit Count
30
Registration Number
NCT03343652
Locations
🇷🇺

First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

First Posted Date
2017-11-08
Last Posted Date
2023-11-09
Lead Sponsor
BeiGene
Target Recruit Count
590
Registration Number
NCT03336333
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Augusta University, Augusta, Georgia, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

and more 175 locations

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

First Posted Date
2017-10-20
Last Posted Date
2018-05-22
Lead Sponsor
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Target Recruit Count
100
Registration Number
NCT03315520
Locations
🇷🇺

The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

First Posted Date
2017-10-16
Last Posted Date
2024-10-24
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
21
Registration Number
NCT03311126
Locations
🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

First Posted Date
2017-09-01
Last Posted Date
2024-11-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
95
Registration Number
NCT03269669
Locations
🇺🇸

Mercy Hospital Saint Louis, Saint Louis, Missouri, United States

🇺🇸

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States

🇺🇸

Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States

and more 430 locations

Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

First Posted Date
2017-08-23
Last Posted Date
2021-06-07
Lead Sponsor
St. Petersburg State Pavlov Medical University
Target Recruit Count
30
Registration Number
NCT03259529
Locations
🇷🇺

First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

Bendamustine and Melphalan in Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Melphalan
Drug: Bendamustine
First Posted Date
2017-06-14
Last Posted Date
2021-08-05
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
121
Registration Number
NCT03187223
Locations
🇨🇭

Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

First Posted Date
2016-12-19
Last Posted Date
2024-07-11
Lead Sponsor
University of Arizona
Target Recruit Count
50
Registration Number
NCT02996773
Locations
🇺🇸

The University of Arizona Cancer Center, Tucson, Arizona, United States

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

First Posted Date
2016-11-25
Last Posted Date
2024-11-29
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
635
Registration Number
NCT02972840
Locations
🇻🇳

Research Site, Ho Chi Minh, Vietnam

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

First Posted Date
2016-11-22
Last Posted Date
2024-11-27
Lead Sponsor
Acerta Pharma BV
Target Recruit Count
310
Registration Number
NCT02970318
Locations
🇬🇧

Research Site, Wolverhampton, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy